Please login to the form below

Not currently logged in
Email:
Password:

MRC Technology appoints director of technology transfer

Andrew Farquharson will join the firm from September 1

MRC Technology has named Andrew Farquharson as director of technology transfer, effective from September 1.

Farquharson will lead the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Commenting on his appointment, Farquharson said: “I am greatly looking forward to joining the MRCT team and using my experience to meet the challenges in ensuring that future innovations are protected and translated into meaningful new therapeutic products made available to patients.”

Farquharson has previously held senior intellectual property (IP) roles at AstraZeneca UK and USA, supporting the firm's R&D, business development and government affairs activities.

He currently runs a consultancy practice, which provides IP services to a breadth of life science and pharma clients. 

Farquharson is additionally appointed to the EU Commission's Expert Group, advising on the European Biotech Directive's impact on patent law and R&D activities.

Dr Dave Tapolczay, CEO at MRC Technology, added: “Andrew's extensive experience will support our charity's work to ensure innovative life science research reaches its full potential and benefit a wider range of people. We look forward to having him on board.”

8th July 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics